Tscan Therapeutics Inc(TCRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:09 PM ET (Korea 10/31 05:09)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.91 | Insider Own | 21.33% | Shs Outstand | 63.5M | Perf Week | -14.12% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 24.57% | Insider Trans | - | Shs Float | 53.3M | Perf Month | -45.04% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.19 | Inst Own | 50.36% | Short Float | 4.27% | Perf Quarter | -75.88% |
| Income | -0.12B | P/S | 1.66 | EPS this Y | 20.44% | Inst Trans | 30.65% | Short Ratio | 3.11 | Perf Half Y | -85.7% |
| Sales | 0.01B | P/B | 0.17 | EPS next 5Y | 16.6% | ROA | -50.09% | Short Interest | 2.28M | Perf YTD | -82.55% |
| Book/sh | 1.02 | P/C | 0.12 | EPS past 3/5Y | 28.66% 2.08% | ROE | -95.8% | 52W High | -91.34% ($2.01) | Perf Year | -90.62% |
| Cash/sh | 1.48 | P/FCF | - | Sales past 3/5Y | -8.63% 56.92% | ROIC | -83.79% | 52W Low | -3.06% ($0.18) | Perf 3Y | -95.66% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 17.34% | Gross Margin | 59.47% | Volatility(W/M) | 9.63% 10.58% | Perf 5Y | -98.01% |
| Dividend TTM | - | EV/Sales | 0.36 | Sales Y/Y TTM | 2.15% | Oper. Margin | -1695.15% | ATR (14) | 0.03 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.37 | EPS Q/Q | 17.98% | Profit Margin | -1655.35% | RSI (14) | 25.61 | Recom | 2.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.37 | Sales Q/Q | -65.83% | SMA20 | -22.04% ($0.22) | Beta | 1.14 | Target Price | $2.67 |
| Payout | - | Debt/Eq | 1.32 | Earnings | 2026/8/12 | SMA50 | -51.35% ($0.35) | Rel Volume | 0.45 | Prev Close | $0.19 |
| Employees | 142 | LT Debt/Eq | 1.04 | EPS/Sales Surpr. | 9.23% -43.95% | SMA200 | -79.5% ($0.83) | Avg Volume(3M) | 0.73M | Price | $0.17 |
| IPO | 2021/7/16 | Option/Short | No/Yes | Trades | 496 | Volume | 333,159 | Change | -10.47% |
A next-generation U.S. biotech company developing personalized TCR-T cell therapies through its proprietary "TScan" platform. Leveraging its broad target database called "ImmunoBank," which spans both hematologic malignancies and solid tumors, the company is leading the way in patient-tailored precision immuno-oncology solutions.
Over the past 1 year, on the lower side
92% below its 1-year high.
Traded less than usual. That is 45% of its average volume.
TCRX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $166. Peers typically go for $1,010.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 50.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #495 of 597 in the industry
Based on market cap of $12M.
BIVI#492 BioVie Inc $12M PER - 
ATYR#493 Atyr Pharma Inc $12M PER - 
LPCN#494 Lipocine Inc $12M PER - TCRX#495 Tscan Therapeutics Inc $12M PER - 
CLRB#496 Cellectar Biosciences Inc $11M PER - 
FAQ
What kind of company is TCRX?
TCRX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TCRX?
The market cap of TCRX is approximately $12M, ranking 5,384 within its sector.
What is the 52-week high and low for TCRX?
TCRX has recorded a 52-week high of $2.01 and a low of $0.18.
